Completed study
🡇 Download protocol
🡇 Download SAP
Official Study Title
Immunotherapy Navigated by Serum Presepsin for Infections of the REspiratory tract: the INSPIRE double-blind, randomized, phase IIa exploratory trial
Brief Description
The INSPIRE study is an exploratory, randomised, phase IIa clinical trial which aims to evaluate the potential benefit of presepsin-guided anakinra therapy as an adjuvant to the standard of care treatment in patients with community-acquired pneumonia or hospital-acquired pneumonia by preventing the development of organ dysfunction.
Details
Status: Completed
Study Type: Interventional (Clinical Trial)
Study phase: IIa
Study sites: 5 sites in Greece
Enrolled: 60 participants
ClinicalTrials.gov Identifier: NTC05785442
EudraCT number: 2022-002390-28
Start of trial: October 2022
End of trial: June 28th, 2024
Condition/Disease studied: Infections of the respiratory tract
Keywords: CAP; HAP; Anakinra
Related publications
- Efficacy of anakinra in reducing progression to organ dysfunction in patients with pneumonia (INSPIRE): a randomised, double-blind, placebo-controlled phase IIa trial
The Lancet Regional Health – Europe 2026;62: 101573